# An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection

> **NCT07495007** · PHASE1 · COMPLETED · sponsor: **Zi Diligence Biocenter** · enrollment: 26 (actual)

## Conditions studied

- Bioequivalance
- Post-menopause

## Interventions

- **DRUG:** Progesterone IM of 100 mg
- **DRUG:** Progesterone IM of 100 mg

## Key facts

- **NCT ID:** NCT07495007
- **Lead sponsor:** Zi Diligence Biocenter
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-11-10
- **Primary completion:** 2025-12-28
- **Final completion:** 2025-12-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07495007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07495007, "An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07495007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*